🎥 HNF Webinar Replay: What NMD670 Means for Patients with CMT

🎥 Webinar Replay: Breaking Barriers – What NMD670 Means for Patients with CMT
🗓️ Originally aired: Thursday, April 3, 2025
📍 Hosted by the Hereditary Neuropathy Foundation (HNF) and NMD Pharma

In this powerful and informative webinar, viewers heard directly from Thomas Holm Pedersen, CEO of NMD Pharma, about the latest updates on the NMD670 Phase 2 SYNAPSE-CMT trial. This groundbreaking study is evaluating the safety and efficacy of NMD670, a potential treatment for patients living with CMT1 and CMT2.

🔍 Webinar Highlights Included:
✅ An overview of how NMD670 may improve muscle activation for people with CMT
✅ A patient-friendly breakdown of the Phase 2 trial – who can participate and what’s involved
✅ A special focus on why CMT2 patients are urgently needed for research progress
✅ A live Q&A session with the experts at NMD Pharma

Whether you're a patient, caregiver, or advocate, this session offered essential insights into emerging treatments for CMT and how to take part in shaping the future of care.

📄 Want to learn more or find a trial site near you?
👉 [Complete this form to be contacted about a clinical trial site in your state https://interland3.donorperfect.net/w...

🔗 Register for the 2025 Summit & Retreat at CMTsummit.org. Stay connected and share this video to help spread awareness at hnf-cure.org
#CMTResearch #NMD670 #CMT2 #ClinicalTrials #HNF #CMTCommunity #BreakingBarriers